• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低密度脂蛋白受体相关蛋白/α2-巨球蛋白受体是组织型纤溶酶原激活物的肝脏受体。

Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator.

作者信息

Bu G, Williams S, Strickland D K, Schwartz A L

机构信息

Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110.

出版信息

Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7427-31. doi: 10.1073/pnas.89.16.7427.

DOI:10.1073/pnas.89.16.7427
PMID:1502154
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC49723/
Abstract

Tissue-type plasminogen activator (t-PA), a serine protease that catalyzes the initial and rate-limiting step in the fibrinolytic cascade, is cleared rapidly in vivo by the liver. Using chemical crosslinking, we have recently identified a plasminogen-activator inhibitor type 1 (PAI-1)-independent t-PA clearance receptor on rat hepatoma MH1C1 cells with a relative molecular mass of approximately 500 kDa. Another recently identified membrane receptor, low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP/alpha 2MR), was also detected on MH1C1 hepatoma cells by using immunoprecipitation with anti-LRP/alpha 2MR antibody. When analyzed by SDS/PAGE, we found the t-PA receptor identified on MH1C1 cells comigrated with the large subunit of LRP/alpha 2MR. The t-PA receptor was immunoprecipitated by an anti-LRP/alpha 2MR antibody after chemical crosslinking of specifically bound 125I-labeled t-PA to its receptor. Through chemical crosslinking studies, we found that t-PA and methylamine-activated alpha 2-macroglobulin could bind to LRP/alpha 2MR simultaneously without competing with one another for binding, suggesting that the two ligands bound to two independent sites on the LRP/alpha 2MR molecule. Furthermore, a 39-kDa protein, which modulates ligand binding to LRP/alpha 2MR, was also found to inhibit t-PA binding to its receptor. These data thus show that the t-PA clearance receptor identified on MH1C1 hepatoma cells is LRP/alpha 2MR.

摘要

组织型纤溶酶原激活剂(t-PA)是一种丝氨酸蛋白酶,可催化纤维蛋白溶解级联反应的起始和限速步骤,在体内会被肝脏迅速清除。我们最近利用化学交联技术,在大鼠肝癌MH1C1细胞上鉴定出一种相对分子质量约为500 kDa的纤溶酶原激活剂抑制剂1型(PAI-1)非依赖性t-PA清除受体。通过用抗LRP/α2MR抗体进行免疫沉淀,在MH1C1肝癌细胞上还检测到了另一种最近鉴定出的膜受体,即低密度脂蛋白受体相关蛋白/α2巨球蛋白受体(LRP/α2MR)。当通过SDS/PAGE分析时,我们发现MH1C1细胞上鉴定出的t-PA受体与LRP/α2MR的大亚基迁移率相同。在将特异性结合的125I标记的t-PA与其受体进行化学交联后,t-PA受体可被抗LRP/α2MR抗体免疫沉淀。通过化学交联研究,我们发现t-PA和甲胺激活的α2巨球蛋白可以同时结合到LRP/α2MR上,而不会相互竞争结合,这表明这两种配体结合到LRP/α2MR分子上的两个独立位点。此外,还发现一种调节配体与LRP/α2MR结合的39 kDa蛋白也能抑制t-PA与其受体的结合。因此,这些数据表明在MH1C1肝癌细胞上鉴定出的t-PA清除受体是LRP/α2MR。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/49723/263872df9b4e/pnas01090-0151-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/49723/25a73c828369/pnas01090-0150-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/49723/3169bc31c69d/pnas01090-0151-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/49723/263872df9b4e/pnas01090-0151-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/49723/25a73c828369/pnas01090-0150-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/49723/3169bc31c69d/pnas01090-0151-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/49723/263872df9b4e/pnas01090-0151-b.jpg

相似文献

1
Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator.低密度脂蛋白受体相关蛋白/α2-巨球蛋白受体是组织型纤溶酶原激活物的肝脏受体。
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7427-31. doi: 10.1073/pnas.89.16.7427.
2
Identification of domains on the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein.鉴定39 kDa蛋白上抑制配体与低密度脂蛋白受体相关蛋白结合的结构域。
J Biol Chem. 1993 Oct 15;268(29):22046-54.
3
Interaction of a 39 kDa protein with the low-density-lipoprotein-receptor-related protein (LRP) on rat hepatoma cells.一种39 kDa蛋白质与大鼠肝癌细胞上低密度脂蛋白受体相关蛋白(LRP)的相互作用。
Biochem J. 1993 Dec 15;296 ( Pt 3)(Pt 3):867-75. doi: 10.1042/bj2960867.
4
Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.组织型纤溶酶原激活剂通过人肝癌HepG2细胞上的低密度脂蛋白受体相关蛋白进行受体介导的内吞作用。
J Biol Chem. 1993 Jun 15;268(17):13002-9.
5
Binding analysis of amino-terminal and carboxyl-terminal regions of the 39-kDa protein to the low density lipoprotein receptor-related protein.
J Biol Chem. 1994 Feb 4;269(5):3325-30.
6
Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.通过化学交联鉴定大鼠肝癌细胞上组织型纤溶酶原激活物(t-PA)结合蛋白并对其进行部分特性分析。一种1型纤溶酶原激活物抑制剂非依赖性t-PA受体。
J Biol Chem. 1992 Aug 5;267(22):15595-602.
7
39-kD protein inhibits tissue-type plasminogen activator clearance in vivo.39-kD蛋白在体内抑制组织型纤溶酶原激活物的清除。
J Clin Invest. 1993 Aug;92(2):937-44. doi: 10.1172/JCI116669.
8
Sites within the 39-kDa protein important for regulating ligand binding to the low-density lipoprotein receptor-related protein.39 kDa蛋白内对调节配体与低密度脂蛋白受体相关蛋白结合很重要的位点。
Biochemistry. 1995 Mar 14;34(10):3404-15. doi: 10.1021/bi00010a032.
9
Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.参与尿激酶-1型抑制剂复合物和尿激酶原与内吞性α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白结合的区域。尿激酶受体保护尿激酶原不与内吞性受体结合的证据。
J Biol Chem. 1994 Oct 14;269(41):25668-76.
10
Alpha 2-macroglobulin-proteinase complexes, plasminogen activator inhibitor type-1-plasminogen activator complexes, and receptor-associated protein bind to a region of the alpha 2-macroglobulin receptor containing a cluster of eight complement-type repeats.α2-巨球蛋白-蛋白酶复合物、1型纤溶酶原激活物抑制剂-纤溶酶原激活物复合物以及受体相关蛋白与α2-巨球蛋白受体的一个区域结合,该区域含有一簇八个补体样重复序列。
J Biol Chem. 1993 Jun 25;268(18):13691-6.

引用本文的文献

1
A facultative plasminogen-independent thrombolytic enzyme from Sipunculus nudus.一种来自裸体方格星虫的兼性非纤溶酶原依赖性溶栓酶。
Nat Commun. 2025 Apr 24;16(1):3852. doi: 10.1038/s41467-025-58915-y.
2
Macrophage Function Modulated by tPA Signaling in Mouse Experimental Kidney Disease Models.tPA 信号对小鼠实验性肾病模型中巨噬细胞功能的调节。
Int J Mol Sci. 2023 Jul 4;24(13):11067. doi: 10.3390/ijms241311067.
3
Low-density lipoprotein receptor-related protein-1 (LRP1) in the glial lineage modulates neuronal excitability.神经胶质谱系中的低密度脂蛋白受体相关蛋白1(LRP1)调节神经元兴奋性。

本文引用的文献

1
Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits.人外源性(组织型)纤溶酶原激活剂在兔体内的周转率。
Thromb Haemost. 1981 Oct;46(3):658-61.
2
Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.培养的人黑色素瘤细胞分泌的纤溶酶原激活物的纯化及特性分析
J Biol Chem. 1981 Jul 10;256(13):7035-41.
3
Clot-selective coronary thrombolysis with tissue-type plasminogen activator.使用组织型纤溶酶原激活剂进行冠状动脉血栓选择性溶栓治疗。
Front Netw Physiol. 2023 Jun 13;3:1190240. doi: 10.3389/fnetp.2023.1190240. eCollection 2023.
4
Endocrine Regulation of Microvascular Receptor-Mediated Transcytosis and Its Therapeutic Opportunities: Insights by PCSK9-Mediated Regulation.微血管受体介导的转胞吞作用的内分泌调节及其治疗机会:PCSK9介导的调节见解
Pharmaceutics. 2023 Apr 18;15(4):1268. doi: 10.3390/pharmaceutics15041268.
5
The LRP1/CD91 ligands, tissue-type plasminogen activator, α-macroglobulin, and soluble cellular prion protein have distinct co-receptor requirements for activation of cell-signaling.LRP1/CD91 配体、组织型纤溶酶原激活物、α-巨球蛋白和可溶性细胞朊蛋白在激活细胞信号转导方面具有不同的共受体需求。
Sci Rep. 2022 Oct 20;12(1):17594. doi: 10.1038/s41598-022-22498-1.
6
Cryo-EM structures reveal the dynamic transformation of human alpha-2-macroglobulin working as a protease inhibitor.冷冻电镜结构揭示了作为蛋白酶抑制剂的人α-2-巨球蛋白的动态转变。
Sci China Life Sci. 2022 Dec;65(12):2491-2504. doi: 10.1007/s11427-022-2139-2. Epub 2022 Jun 28.
7
tPA-NMDAR Signaling Blockade Reduces the Incidence of Intracerebral Aneurysms.tPA-NMDAR 信号阻断可降低颅内动脉瘤的发生率。
Transl Stroke Res. 2022 Dec;13(6):1005-1016. doi: 10.1007/s12975-022-01004-9. Epub 2022 Mar 21.
8
Plasminogen activator receptor assemblies in cell signaling, innate immunity, and inflammation.纤溶酶原激活物受体在细胞信号转导、固有免疫和炎症中的组装。
Am J Physiol Cell Physiol. 2021 Oct 1;321(4):C721-C734. doi: 10.1152/ajpcell.00269.2021. Epub 2021 Aug 18.
9
Complement C1q Interacts With LRP1 Clusters II and IV Through a Site Close but Different From the Binding Site of Its C1r and C1s-Associated Proteases.补体 C1q 通过一个接近但不同于其 C1r 和 C1s 相关蛋白酶结合位点的位点与 LRP1 簇 II 和 IV 相互作用。
Front Immunol. 2020 Oct 21;11:583754. doi: 10.3389/fimmu.2020.583754. eCollection 2020.
10
The multifaceted role of plasminogen in inflammation.纤溶酶原在炎症中的多效性作用。
Cell Signal. 2020 Nov;75:109761. doi: 10.1016/j.cellsig.2020.109761. Epub 2020 Aug 28.
Science. 1983 Jun 10;220(4602):1181-3. doi: 10.1126/science.6602378.
4
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.组织型纤溶酶原激活剂用于进展性心肌梗死患者的冠状动脉溶栓治疗。
N Engl J Med. 1984 Mar 8;310(10):609-13. doi: 10.1056/NEJM198403083101001.
5
The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA.人类低密度脂蛋白受体:一种在其信使核糖核酸中含有多个Alu序列的富含半胱氨酸的蛋白质。
Cell. 1984 Nov;39(1):27-38. doi: 10.1016/0092-8674(84)90188-0.
6
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.在噬菌体T4头部组装过程中结构蛋白的切割
Nature. 1970 Aug 15;227(5259):680-5. doi: 10.1038/227680a0.
7
Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans.重组人组织型纤溶酶原激活剂(rt-PA)在人体内的药代动力学及全身纤维蛋白溶解作用
J Pharmacol Exp Ther. 1985 Nov;235(2):506-12.
8
Catabolism of human tissue plasminogen activator in mice.
Blood. 1985 Mar;65(3):539-44.
9
Hepatic clearance of tissue-type plasminogen activator in rats.
Thromb Haemost. 1985 Oct 30;54(3):661-4.
10
A receptor-mediated pathway for cholesterol homeostasis.胆固醇稳态的受体介导途径。
Science. 1986 Apr 4;232(4746):34-47. doi: 10.1126/science.3513311.